PD-1 Inhibitors in Recurrent or Metastatic Oral Squamous Cell Carcinoma: Clinical Evidence, Patient Selection, and Immune-Related Toxicities. J Oral Health Dent Ther. 2026;1(1):27-31. doi:10.68041/johdt.v1i1/06